article_metadata: Lin Shui Ke Cheng Xiaofen Li Pixian Shui Shuangshuang Li Yang Peng Jian Li Fengzhu Guo Cheng Yi Dan Cao
article_metadata: 10.3389/fimmu.2020.01127
article_metadata: Front Immunol
article_metadata: 2020 Jun 19;11:1127.
article_metadata: pd-1 inhibitor case report chemotherapy combination therapy durable response good tolerance metastatic pancreatic ductal adenocarcinoma
article_metadata: CC BY
article_metadata: https://pubmed.ncbi.nlm.nih.gov/32636837/
article_metadata: Antineoplastic Combined Chemotherapy Protocols / administration & dosage Carcinoma, Pancreatic Ductal / drug therapy Pancreatic Neoplasms / drug therapy
article_metadata: Antineoplastic Combined Chemotherapy Protocols / administration & dosage Carcinoma, Pancreatic Ductal / drug therapy Pancreatic Neoplasms / drug therapy Case Reports Research Support, Non-U.S. Gov't Albumins / administration & dosage Antibodies, Monoclonal, Humanized / administration & dosage B7-H1 Antigen / metabolism Carcinoma, Pancreatic Ductal / metabolism Carcinoma, Pancreatic Ductal / secondary Deoxycytidine / administration & dosage Deoxycytidine / analogs & derivatives Gemcitabine Humans Immune Checkpoint Inhibitors / administration & dosage Immunohistochemistry Male Middle Aged Paclitaxel / administration & dosage Pancreatic Neoplasms / metabolism Pancreatic Neoplasms / pathology Tomography, X-Ray Computed Treatment Outcome 130-nm albumin-bound paclitaxel Albumins Antibodies, Monoclonal, Humanized B7-H1 Antigen CD274 protein, human Immune Checkpoint Inhibitors Deoxycytidine toripalimab Paclitaxel Gemcitabine
article_metadata: PMC7318868
article_metadata: 32636837
article_metadata: Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma
article_metadata: 2020